121
Views
25
CrossRef citations to date
0
Altmetric
Review

Targeting eNOS and beyond: emerging heterogeneity of the role of endothelial Rho proteins in stroke protection

&
Pages 1171-1186 | Published online: 09 Jan 2014

References

  • Murphy S, Gibson CL. Nitric oxide, ischaemia and brain inflammation. Biochem. Soc. Trans.35(Pt 5), 1133–1137 (2007).
  • Ginsberg MD. Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology55(3), 363–389 (2008).
  • Mehta SL, Manhas N, Raghubir R. Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res. Rev.54(1), 34–66 (2007).
  • Schlachetzki F, Zhang Y, Boado RJ, Pardridge WM. Gene therapy of the brain: the trans-vascular approach. Neurology62(8), 1275–1281 (2004).
  • Rudic RD, Sessa WC. Nitric oxide in endothelial dysfunction and vascular remodeling: clinical correlates and experimental links. Am. J. Hum. Genet.64(3), 673–677 (1999).
  • Samdani AF, Dawson TM, Dawson VL. Nitric oxide synthase in models of focal ischemia. Stroke28(6), 1283–1288 (1997).
  • Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem. J.298(Pt 2), 249–258 (1994).
  • Murphy S, Simmons ML, Agullo L et al. Synthesis of nitric oxide in CNS glial cells. Trends Neurosci.16(8), 323–328 (1993).
  • Moro MA, Cardenas A, Hurtado O, Leza JC, Lizasoain I. Role of nitric oxide after brain ischaemia. Cell Calcium36(3–4), 265–275 (2004).
  • Malinski T, Bailey F, Zhang ZG, Chopp M. Nitric oxide measured by a porphyrinic microsensor in rat brain after transient middle cerebral artery occlusion. J. Cereb. Blood Flow Metab.13(3), 355–358 (1993).
  • Huang Z, Huang PL, Panahian N et al. Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science265(5180), 1883–1885 (1994).
  • Iadecola C, Zhang F, Casey R, Nagayama M, Ross ME. Delayed reduction of ischemic brain injury and neurological deficits in mice lacking the inducible nitric oxide synthase gene. J. Neurosci.17(23), 9157–9164 (1997).
  • Endres M, Scott G, Namura S et al. Role of peroxynitrite and neuronal nitric oxide synthase in the activation of poly (ADP-ribose) synthetase in a murine model of cerebral ischemia–reperfusion. Neurosci. Lett.248(1), 41–44 (1998).
  • Koppenol WH, Moreno JJ, Pryor WA, Ischiropoulos H, Beckman JS. Peroxynitrite, a cloaked oxidant formed by nitric oxide and superoxide. Chem. Res. Toxicol.5(6), 834–842 (1992).
  • Clementi E, Brown GC, Feelisch M, Moncada S. Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. Proc. Natl Acad. Sci. USA95(13), 7631–7636 (1998).
  • Huang Z, Huang PL, Ma J et al. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine. J. Cereb. Blood Flow Metab.16(5), 981–987 (1996).
  • Lo EH, Hara H, Rogowska J et al. Temporal correlation mapping analysis of the hemodynamic penumbra in mutant mice deficient in endothelial nitric oxide synthase gene expression. Stroke27(8), 1381–1385 (1996).
  • Dalkara T, Morikawa E, Panahian N, Moskowitz MA. Blood flow-dependent functional recovery in a rat model of focal cerebral ischemia. Am. J. Physiol.267(2 Pt 2), H678–H683 (1994).
  • Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am. J. Physiol. Regul. Integr. Comp. Physiol.284(1), R1–R12 (2003).
  • Fulton D, Gratton JP, Sessa WC. Post-translational control of endothelial nitric oxide synthase: why isn’t calcium/calmodulin enough? J. Pharmacol. Exp. Ther.299(3), 818–824 (2001).
  • Liu VW, Huang PL. Cardiovascular roles of nitric oxide: a review of insights from nitric oxide synthase gene disrupted mice. Cardiovasc. Res.77(1), 19–29 (2008).
  • Dimmeler S, Fleming I, Fisslthaler B et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature399(6736), 601–605 (1999).
  • Fulton D, Gratton JP, McCabe TJ et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature399(6736), 597–601 (1999).
  • Shaul PW. Regulation of endothelial nitric oxide synthase: location, location, location. Annu. Rev. Physiol.64, 749–774 (2002).
  • Reinoso RF, Sanchez Navarro A, Garcia MJ, Prous JR. Preclinical pharmacokinetics of statins. Methods Find Exp. Clin. Pharmacol.24(9), 593–613 (2002).
  • Endres M. Statins and stroke. J. Cereb. Blood Flow Metab.25(9), 1093–1110 (2005).
  • Endres M, Laufs U, Huang Z et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc. Natl Acad. Sci. USA95(15), 8880–8885 (1998).
  • Yamada M, Huang Z, Dalkara T et al. Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment. J. Cereb. Blood Flow Metab.20(4), 709–717 (2000).
  • Sironi L, Cimino M, Guerrini U et al. Treatment with statins after induction of focal ischemia in rats reduces the extent of brain damage. Arterioscler. Thromb. Vasc. Biol.23(2), 322–327 (2003).
  • Kawashima S, Yamashita T, Miwa Y et al. HMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats. Stroke34(1), 157–163 (2003).
  • Laufs U. Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur J. Clin. Pharmacol.58(11), 719–731 (2003).
  • Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J. Clin. Invest.101(12), 2711–2719 (1998).
  • Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J. Biol. Chem.273(37), 24266–24271 (1998).
  • Laufs U, Endres M, Stagliano N et al. Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J. Clin. Invest.106(1), 15–24 (2000).
  • Rikitake Y, Kim HH, Huang Z et al. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke36(10), 2251–2257 (2005).
  • Dimmeler S, Aicher A, Vasa M et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J. Clin. Invest.108(3), 391–397 (2001).
  • Kureishi Y, Luo Z, Shiojima I et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med.6(9), 1004–1010 (2000).
  • Wolfrum S, Dendorfer A, Rikitake Y et al. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler. Thromb. Vasc. Biol.24(10), 1842–1847 (2004).
  • Shin HK, Salomone S, Potts EM et al. Rho-kinase inhibition acutely augments blood flow in focal cerebral ischemia via endothelial mechanisms. J. Cereb. Blood Flow Metab.27(5), 998–1009 (2007).
  • Atochin DN, Wang A, Liu VW et al. The phosphorylation state of eNOS modulates vascular reactivity and outcome of cerebral ischemia in vivo. J. Clin. Invest.117(7), 1961–1967 (2007).
  • Asahi M, Huang Z, Thomas S et al. Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia. J. Cereb. Blood Flow Metab.25(6), 722–729 (2005).
  • Zhang L, Zhang ZG, Ding GL et al. Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat. Circulation112(22), 3486–3494 (2005).
  • Mayanagi K, Katakam PV, Gaspar T, Domoki F, Busija DW. Acute treatment with rosuvastatin protects insulin resistant (C57BL/6J ob/ob) mice against transient cerebral ischemia. J. Cereb. Blood Flow Metab.28(12), 1927–1935 (2008).
  • Taylor WC, Landau WM. Atherosclerosis and stroke. Ann. Neurol.28(1), 108–109 (1990).
  • Atkins D, Psaty BM, Koepsell TD, Longstreth WT Jr, Larson EB. Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomized, controlled trials. Ann. Intern. Med.119(2), 136–145 (1993).
  • Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA278(4), 313–321 (1997).
  • Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N. Engl. J. Med.320(14), 904–910 (1989).
  • Blood pressure, cholesterol, and stroke in eastern Asia. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Lancet352(9143), 1801–1807 (1998).
  • Hachinski V, Graffagnino C, Beaudry M et al. Lipids and stroke: a paradox resolved. Arch. Neurol.53(4), 303–308 (1996).
  • Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet360(9326), 7–22 (2002).
  • Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet344(8934), 1383–1389 (1994).
  • Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med.335(14), 1001–1009 (1996).
  • Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N. Engl. J. Med.339(19), 1349–1357 (1998).
  • Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation97(15), 1440–1445 (1998).
  • Byington RP, Davis BR, Plehn JF et al. Reduction of stroke events with pravastatin: the prospective pravastatin pooling (PPP) project. Circulation103(3), 387–392 (2001).
  • Collins R, Armitage J, Parish S, Sleight P, Peto R. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet363(9411), 757–767 (2004).
  • Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med.333(20), 1301–1307 (1995).
  • Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet360(9346), 1623–1630 (2002).
  • Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial – lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet361(9364), 1149–1158 (2003).
  • Jonsson N, Asplund K. Does pretreatment with statins improve clinical outcome after stroke? A pilot case-referent study. Stroke32(5), 1112–1115 (2001).
  • Thomas M, Mann J. Increased thrombotic vascular events after change of statin. Lancet352(9143), 1830–1831 (1998).
  • Heeschen C, Hamm CW, Laufs U et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation105(12), 1446–1452 (2002).
  • Amarenco P, Bogousslavsky J, Callahan A, 3rd et al. High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med.355(6), 549–559 (2006).
  • Goldstein LB, Amarenco P, Szarek M et al. Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study. Neurology70(24 Pt 2), 2364–2370 (2008).
  • Vergouwen MD, de Haan RJ, Vermeulen M, Roos YB. Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease. Stroke39(2), 497–502 (2008).
  • Bang OY, Saver JL, Liebeskind DS et al. Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis. Neurology68(10), 737–742 (2007).
  • Mascitelli L, Pezzetta F. Low LDL cholesterol, statins, and brain hemorrhage: should we worry? Neurology69(10), 1061–1062 (2007).
  • Kim HH, Sawada N, Soydan G et al. Additive effects of statin and dipyridamole on cerebral blood flow and stroke protection. J. Cereb. Blood Flow Metab.28(7), 1285–1293 (2008).
  • Nishimura Y, Ito T, Saavedra JM. Angiotensin II AT (1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke31(10), 2478–2486 (2000).
  • Saavedra JM, Benicky J, Zhou J. Mechanisms of the anti-ischemic effect of angiotensin II AT (1) receptor antagonists in the brain. Cell Mol. Neurobiol.26(7–8), 1099–1111 (2006).
  • Culman J, Zhao Y, Gohlke P, Herdegen T. PPAR-γ: therapeutic target for ischemic stroke. Trends Pharmacol. Sci.28(5), 244–249 (2007).
  • Chu K, Lee ST, Koo JS et al. Peroxisome proliferator-activated receptor-γ-agonist, rosiglitazone, promotes angiogenesis after focal cerebral ischemia. Brain Res.1093(1), 208–218 (2006).
  • Tsai SK, Hung LM, Fu YT et al. Resveratrol neuroprotective effects during focal cerebral ischemia injury via nitric oxide mechanism in rats. J. Vasc. Surg.46(2), 346–353 (2007).
  • Endres M, Gertz K, Lindauer U et al. Mechanisms of stroke protection by physical activity. Ann. Neurol.54(5), 582–590 (2003).
  • Sasaki Y, Noguchi T, Yamamoto E et al. Effects of voluntary exercise on cerebral thrombosis and endothelial function in spontaneously hypertensive rats (SHRSP/Izm). Clin. Exp. Pharmacol. Physiol.31(Suppl. 2), S47–S48 (2004).
  • Laufs U, Werner N, Link A et al. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation109(2), 220–226 (2004).
  • Gertz K, Priller J, Kronenberg G et al. Physical activity improves long-term stroke outcome via endothelial nitric oxide synthase-dependent augmentation of neovascularization and cerebral blood flow. Circ. Res.99(10), 1132–1140 (2006).
  • Hafezi-Moghadam A, Simoncini T, Yang Z et al. Acute cardiovascular protective effects of corticosteroids are mediated by nontranscriptional activation of endothelial nitric oxide synthase. Nat. Med.8(5), 473–479 (2002).
  • Limbourg FP, Huang Z, Plumier JC et al. Rapid nontranscriptional activation of endothelial nitric oxide synthase mediates increased cerebral blood flow and stroke protection by corticosteroids. J. Clin. Invest.110(11), 1729–1738 (2002).
  • Simoncini T, Hafezi-Moghadam A, Brazil DP et al. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature407(6803), 538–541 (2000).
  • Hiroi Y, Kim HH, Ying H et al. Rapid nongenomic actions of thyroid hormone. Proc. Natl Acad. Sci. USA103(38), 14104–14109 (2006).
  • Murohara T, Asahara T, Silver M et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J. Clin. Invest.101(11), 2567–2578 (1998).
  • Aicher A, Heeschen C, Mildner-Rihm C et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat. Med.9(11), 1370–1376 (2003).
  • Ovbiagele B, Saver JL, Starkman S et al. Statin enhancement of collateralization in acute stroke. Neurology68(24), 2129–2131 (2007).
  • Chen J, Zacharek A, Zhang C et al. Endothelial nitric oxide synthase regulates brain-derived neurotrophic factor expression and neurogenesis after stroke in mice. J. Neurosci.25(9), 2366–2375 (2005).
  • Lee CD, Folsom AR, Blair SN. Physical activity and stroke risk: a meta-analysis. Stroke34(10), 2475–2481 (2003).
  • Di Castelnuovo A, Rotondo S, Iacoviello L, Donati MB, De Gaetano G. Meta-analysis of wine and beer consumption in relation to vascular risk. Circulation105(24), 2836–2844 (2002).
  • Thomas D, Bath PM, Lees K et al. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). Int. J. Stroke1(4), 245–249 (2006).
  • Hassan A, Gormley K, O’Sullivan M et al. Endothelial nitric oxide gene haplotypes and risk of cerebral small-vessel disease. Stroke35(3), 654–659 (2004).
  • Wang XL, Wang J. Endothelial nitric oxide synthase gene sequence variations and vascular disease. Mol. Genet. Metab.70(4), 241–251 (2000).
  • Starke RM, Kim GH, Komotar RJ et al. Endothelial nitric oxide synthase gene single-nucleotide polymorphism predicts cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J. Cereb. Blood Flow Metab.28(6), 1204–1211 (2008).
  • Ko NU, Rajendran P, Kim H et al. Endothelial nitric oxide synthase polymorphism (-786T – C) and increased risk of angiographic vasospasm after aneurysmal subarachnoid hemorrhage. Stroke39(4), 1103–1108 (2008).
  • McGirt MJ, Lynch JR, Parra A et al. Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage. Stroke33(12), 2950–2956 (2002).
  • White BC, Sullivan JM, DeGracia DJ et al. Brain ischemia and reperfusion: molecular mechanisms of neuronal injury. J. Neurol. Sci.179(S 1–2), 1–33 (2000).
  • Lok J, Gupta P, Guo S et al. Cell–cell signaling in the neurovascular unit. Neurochem. Res.32(12), 2032–2045 (2007).
  • Abbott NJ, Ronnback L, Hansson E. Astrocyte–endothelial interactions at the blood–brain barrier. Nat. Rev. Neurosci.7(1), 41–53 (2006).
  • Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in stroke. Nat. Rev. Neurosci.4(5), 399–415 (2003).
  • Wu D. Neuroprotection in experimental stroke with targeted neurotrophins. NeuroRx2(1), 120–128 (2005).
  • Lindsay RM. Neuron saving schemes. Nature373(6512), 289–290 (1995).
  • Kitagawa H, Hayashi T, Mitsumoto Y et al. Reduction of ischemic brain injury by topical application of glial cell line-derived neurotrophic factor after permanent middle cerebral artery occlusion in rats. Stroke29(7), 1417–1422 (1998).
  • Tomac A, Lindqvist E, Lin LF et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature373(6512), 335–339 (1995).
  • Harvey BK, Hoffer BJ, Wang Y. Stroke and TGF-β proteins: glial cell line-derived neurotrophic factor and bone morphogenetic protein. Pharmacol. Ther.105(2), 113–125 (2005).
  • Lang AE, Gill S, Patel NK et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol.59(3), 459–466 (2006).
  • Patel NK, Bunnage M, Plaha P et al. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann. Neurol.57(2), 298–302 (2005).
  • Leventhal C, Rafii S, Rafii D, Shahar A, Goldman SA. Endothelial trophic support of neuronal production and recruitment from the adult mammalian subependyma. Mol. Cell Neurosci.13(6), 450–464 (1999).
  • Chen J, Zhang C, Jiang H et al. Atorvastatin induction of VEGF and BDNF promotes brain plasticity after stroke in mice. J. Cereb. Blood Flow Metab.25(2), 281–290 (2005).
  • Shen Q, Goderie SK, Jin L et al. Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells. Science304(5675), 1338–1340 (2004).
  • del Zoppo GJ, Mabuchi T. Cerebral microvessel responses to focal ischemia. J. Cereb. Blood Flow Metab.23(8), 879–894 (2003).
  • Cunningham LA, Wetzel M, Rosenberg GA. Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia50(4), 329–339 (2005).
  • Lipton P. Ischemic cell death in brain neurons. Physiol. Rev.79(4), 1431–1568 (1999).
  • Jiang X, Namura S, Nagata I. Matrix metalloproteinase inhibitor KB-R7785 attenuates brain damage resulting from permanent focal cerebral ischemia in mice. Neurosci. Lett.305(1), 41–44 (2001).
  • Heasman SJ, Ridley AJ. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat. Rev. Mol. Cell Biol.9(9), 690–701 (2008).
  • Sawada N, Salomone S, Kim HH, Kwiatkowski DJ, Liao JK. Regulation of endothelial nitric oxide synthase and postnatal angiogenesis by Rac1. Circ. Res.103(4), 360–368 (2008).
  • Tan W, Palmby TR, Gavard J et al. An essential role for Rac1 in endothelial cell function and vascular development. FASEB J.22(6), 1829–1838 (2008).
  • Sawada N, Kim HH, Moskowitz MA, Liao JK. Rac1 is a critical mediator of endothelium-derived neurotrophic activity. Sci. Signal2(61), ra10 (2009).
  • Bierl C, Voetsch B, Jin RC, Handy DE, Loscalzo J. Determinants of human plasma glutathione peroxidase (GPx-3) expression. J. Biol. Chem.279(26), 26839–26845 (2004).
  • Voetsch B, Jin RC, Bierl C et al. Promoter polymorphisms in the plasma glutathione peroxidase (GPx-3) gene: a novel risk factor for arterial ischemic stroke among young adults and children. Stroke38(1), 41–49 (2007).
  • Gabai VL, Sherman MY. Invited review: Interplay between molecular chaperones and signaling pathways in survival of heat shock. J. Appl. Physiol.92(4), 1743–1748 (2002).
  • Kamradt MC, Chen F, Sam S, Cryns VL. The small heat shock protein α B-crystallin negatively regulates apoptosis during myogenic differentiation by inhibiting caspase-3 activation. J. Biol. Chem.277(41), 38731–38736 (2002).
  • Beere HM. Stressed to death: regulation of apoptotic signaling pathways by the heat shock proteins. Sci. STKE2001(93), RE1 (2001).
  • Bornstein P, Agah A, Kyriakides TR. The role of thrombospondins 1 and 2 in the regulation of cell–matrix interactions, collagen fibril formation, and the response to injury. Int. J. Biochem. Cell Biol.36(6), 1115–1125 (2004).
  • Bornstein P. Thrombospondins as matricellular modulators of cell function. J. Clin. Invest.107(8), 929–934 (2001).
  • Baloh RH, Tansey MG, Lampe PA et al. Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRα3–RET receptor complex. Neuron21(6), 1291–1302 (1998).
  • Reuss B, von Bohlen und Halbach O. Fibroblast growth factors and their receptors in the central nervous system. Cell Tissue Res.313(2), 139–157 (2003).
  • Junier MP. What role (s) for TGFα in the central nervous system? Prog Neurobiol, 62(5), 443–473 (2000).
  • Wang Y, Chang CF, Morales M, Chiang YH, Hoffer J. Protective effects of glial cell line-derived neurotrophic factor in ischemic brain injury. Ann. NY Acad. Sci.962, 423–437 (2002).
  • Honma Y, Araki T, Gianino S et al. Artemin is a vascular-derived neurotropic factor for developing sympathetic neurons. Neuron35(2), 267–282 (2002).
  • Damon DH, Teriele JA, Marko SB. Vascular-derived artemin: a determinant of vascular sympathetic innervation? Am. J. Physiol. Heart Circ. Physiol.293(1), H266–H273 (2007).
  • Bespalov MM, Saarma M. GDNF family receptor complexes are emerging drug targets. Trends Pharmacol. Sci.28(2), 68–74 (2007).
  • Baloh RH, Gorodinsky A, Golden JP et al. GFRα3 is an orphan member of the GDNF/neurturin/persephin receptor family. Proc. Natl Acad. Sci. USA95(10), 5801–5806 (1998).
  • Rosenblad C, Gronborg M, Hansen C et al.In vivo protection of nigral dopamine neurons by lentiviral gene transfer of the novel GDNF-family member neublastin/artemin. Mol. Cell Neurosci.15(2), 199–214 (2000).
  • Ducray A, Krebs SH, Schaller B et al. GDNF family ligands display distinct action profiles on cultured GABAergic and serotonergic neurons of rat ventral mesencephalon. Brain Res.1069(1), 104–112 (2006).
  • Bonde C, Kristensen BW, Blaabjerg M et al. GDNF and neublastin protect against NMDA-induced excitotoxicity in hippocampal slice cultures. Neuroreport11(18), 4069–4073 (2000).
  • Sakai T, Johnson KJ, Murozono M et al. Plasma fibronectin supports neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and hemostasis. Nat. Med.7(3), 324–330 (2001).
  • Reuss B, Dono R, Unsicker K. Functions of fibroblast growth factor (FGF)-2 and FGF-5 in astroglial differentiation and blood–brain barrier permeability: evidence from mouse mutants. J. Neurosci.23(16), 6404–6412 (2003).
  • Unsicker K, Krieglstein K. Co-activation of TGF-β and cytokine signaling pathways are required for neurotrophic functions. Cytokine Growth Factor Rev.11(1–2), 97–102 (2000).
  • Palmer TD, Willhoite AR, Gage FH. Vascular niche for adult hippocampal neurogenesis. J. Comp. Neurol.425(4), 479–494 (2000).
  • Kumar P, Wu H, McBride JL et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature448(7149), 39–43 (2007).
  • Spencer BJ, Verma IM. Targeted delivery of proteins across the blood–brain barrier. Proc. Natl Acad. Sci. USA104(18), 7594–7599 (2007).
  • Guo S, Kim WJ, Lok J et al. Neuroprotection via matrix-trophic coupling between cerebral endothelial cells and neurons. Proc. Natl Acad. Sci. USA105(21), 7582–7587 (2008).
  • Kennedy J, Hill MD, Ryckborst KJ et al. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol.6(11), 961–969 (2007).
  • Bogousslavsky J, Victor SJ, Salinas EO et al. Fiblast (trafermin) in acute stroke: results of the European–Australian Phase II/III safety and efficacy trial. Cerebrovasc. Dis.14(3–4), 239–251 (2002).
  • Fisher M, Meadows ME, Do T et al. Delayed treatment with intravenous basic fibroblast growth factor reduces infarct size following permanent focal cerebral ischemia in rats. J. Cereb. Blood Flow Metab.15(6), 953–959 (1995).
  • Cleaver O, Melton DA. Endothelial signaling during development. Nat. Med.9(6), 661–668 (2003).
  • Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc. Natl Acad. Sci. USA101(20), 7618–7623 (2004).
  • Tsukahara T, Yonekawa Y, Tanaka K et al. The role of brain-derived neurotrophic factor in transient forebrain ischemia in the rat brain. Neurosurgery34(2), 323–331 (1994).
  • Prehn JH, Backhauss C, Krieglstein J. Transforming growth factor-β1 prevents glutamate neurotoxicity in rat neocortical cultures and protects mouse neocortex from ischemic injury in vivo. J. Cereb. Blood Flow Metab.13(3), 521–525 (1993).
  • Wang Y, Chang CF, Morales M et al. Bone morphogenetic protein-6 reduces ischemia-induced brain damage in rats. Stroke32(9), 2170–2178 (2001).
  • Liu Y, Belayev L, Zhao W et al. The effect of bone morphogenetic protein-7 (BMP-7) on functional recovery, local cerebral glucose utilization and blood flow after transient focal cerebral ischemia in rats. Brain Res.905(1–2), 81–90 (2001).
  • Yao DL, Masonic K, Petullo D et al. Pretreatment with intravenous FGF-13 reduces infarct volume and ameliorates neurological deficits following focal cerebral ischemia in rats. Brain Res.818(1), 140–146 (1999).
  • Ellsworth JL, Garcia R, Yu J, Kindy MS. Fibroblast growth factor-18 reduced infarct volumes and behavioral deficits after transient occlusion of the middle cerebral artery in rats. Stroke34(6), 1507–1512 (2003).
  • Justicia C, Perez-Asensio FJ, Burguete MC, Salom JB, Planas AM. Administration of transforming growth factor-α reduces infarct volume after transient focal cerebral ischemia in the rat. J. Cereb. Blood Flow Metab.21(9), 1097–1104 (2001).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.